Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis

INTRODUCTION: Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was demonstrated in randomised controlled trials; data on its real-world impact in routine clinical practice are starting to emerge. We assessed the effectiveness and safety of mepolizumab prescribed for patients in th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Respir J
Hlavní autoři: Harrison, Tim, Canonica, Giorgio Walter, Chupp, Geoffrey, Lee, Jason, Schleich, Florence, Welte, Tobias, Valero, Antonio, Gemzoe, Kim, Maxwell, Aoife, Joksaite, Sandra, Yang, Shibing, Howarth, Peter, Van Dyke, Melissa K.
Médium: Artigo
Jazyk:Inglês
Vydáno: European Respiratory Society 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7559868/
https://ncbi.nlm.nih.gov/pubmed/32817259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00151-2020
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky